R. Feltell

发表

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

J. Lyons, N. Thompson, M. Squires, 2009, Molecular Cancer Therapeutics.

Biological characterization of AT 7519 , a small-molecule inhibitor of cyclin-dependent kinases , in human tumor cell lines

J. Lyons, N. Thompson, M. Squires, 2009 .

Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.

Paul G Wyatt, Valerio Berdini, V. Berdini, 2008, Journal of medicinal chemistry.

The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer

L. Fazal, M. Reule, J. Lyons, 2012, Cancer science.

Cancer Therapy : Preclinical AT 13148 Is a Novel , Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

P. Jones, P. Workman, M. Walton, 2012 .

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

P. Jones, P. Workman, M. Walton, 2012, Clinical Cancer Research.

A serine proteinase inactivator inhibits chondrocyte-mediated cartilage proteoglycan breakdown occurring in response to proinflammatory cytokines.

R. Feltell, J. Kerrigan, J. Powers, 1998, Archives of Biochemistry and Biophysics.

Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.

Gianni Chessari, Brent Graham, Jose Cosme, 2010, Journal of medicinal chemistry.

Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.

Paul N. Mortenson, M. Congreve, R. Cheng, 2012, ACS medicinal chemistry letters.

Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models

C. Murray, V. Berdini, D. Newell, 2011, Molecular Cancer Therapeutics.

Multiple Metabolic Alterations Exist in Mutant PI3K Cancers, but Only Glucose Is Essential as a Nutrient Source

J. Sninsky, S. Kwok, C. Torrance, 2012, PloS one.

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

W. Qi, V. Lock, J. Lyons, 2007 .

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

P. Jones, P. Workman, M. Walton, 2012, Clinical Cancer Research.